Global Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Multiple System Atrophy (Shy-Drager Syndrome) treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including AFFiRiS AG, Biohaven Pharmaceutical Holding Company, Corestem Inc, Denali Therapeutics Inc, Enterin Inc and others.
A Significant contribution to the Multiple System Atrophy (Shy-Drager Syndrome) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Multiple System Atrophy (Shy-Drager Syndrome) pipeline included 12 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Multiple System Atrophy (Shy-Drager Syndrome) condition and increased access to investments is encouraging growth of Multiple System Atrophy (Shy-Drager Syndrome) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Multiple System Atrophy (Shy-Drager Syndrome) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Multiple System Atrophy (Shy-Drager Syndrome) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Multiple System Atrophy (Shy-Drager Syndrome) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Multiple System Atrophy (Shy-Drager Syndrome). Further, orphan drug status, fast track designation, grants awarded and other special status for Multiple System Atrophy (Shy-Drager Syndrome) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Multiple System Atrophy (Shy-Drager Syndrome) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Multiple System Atrophy (Shy-Drager Syndrome) Pipeline candidates-
A Significant contribution to the Multiple System Atrophy (Shy-Drager Syndrome) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Multiple System Atrophy (Shy-Drager Syndrome) pipeline included 12 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Multiple System Atrophy (Shy-Drager Syndrome) condition and increased access to investments is encouraging growth of Multiple System Atrophy (Shy-Drager Syndrome) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Multiple System Atrophy (Shy-Drager Syndrome) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Multiple System Atrophy (Shy-Drager Syndrome) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Multiple System Atrophy (Shy-Drager Syndrome) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Multiple System Atrophy (Shy-Drager Syndrome). Further, orphan drug status, fast track designation, grants awarded and other special status for Multiple System Atrophy (Shy-Drager Syndrome) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Multiple System Atrophy (Shy-Drager Syndrome) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Multiple System Atrophy (Shy-Drager Syndrome) Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Multiple System Atrophy (Shy-Drager Syndrome) drugs
- Late phase: Phase 3 and in-approval Multiple System Atrophy (Shy-Drager Syndrome) drugs
- Company overview
- Snapshot
- Multiple System Atrophy (Shy-Drager Syndrome) therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Multiple System Atrophy (Shy-Drager Syndrome)- Disease Overview
2.2 Multiple System Atrophy (Shy-Drager Syndrome)- Pipeline Snapshot
2.3 Multiple System Atrophy (Shy-Drager Syndrome)- Pipeline Drugs by Phase
2.4 Multiple System Atrophy (Shy-Drager Syndrome)- Pipeline Drugs by Company
2.5 Multiple System Atrophy (Shy-Drager Syndrome)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 AFFiRiS AG Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.2 Biohaven Pharmaceutical Holding Company Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.3 Corestem Inc Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.4 Denali Therapeutics Inc Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.5 Enterin Inc Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.6 ICB International Inc Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.7 Inhibikase Therapeutics Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.8 MitoDys Therapeutics Ltd Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.9 Modag GmbH Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.10 Neuropore Therapies Inc Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.11 Prana Biotechnology Ltd Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.12 United Neuroscience Inc Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 1 Drug Details
4.2 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 1 Drug Overview
4.3 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 2 Drug Details
5.2 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 2 Drug Overview
5.3 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 3 Drug Details
6.2 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 3 Drug Overview
6.3 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Multiple System Atrophy (Shy-Drager Syndrome)- Pre-clinical Phase Drug Details
7.2 Multiple System Atrophy (Shy-Drager Syndrome)- Pre-clinical Phase Drug Overview
7.3 Multiple System Atrophy (Shy-Drager Syndrome)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Multiple System Atrophy (Shy-Drager Syndrome)- Disease Overview
2.2 Multiple System Atrophy (Shy-Drager Syndrome)- Pipeline Snapshot
2.3 Multiple System Atrophy (Shy-Drager Syndrome)- Pipeline Drugs by Phase
2.4 Multiple System Atrophy (Shy-Drager Syndrome)- Pipeline Drugs by Company
2.5 Multiple System Atrophy (Shy-Drager Syndrome)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 AFFiRiS AG Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.2 Biohaven Pharmaceutical Holding Company Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.3 Corestem Inc Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.4 Denali Therapeutics Inc Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.5 Enterin Inc Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.6 ICB International Inc Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.7 Inhibikase Therapeutics Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.8 MitoDys Therapeutics Ltd Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.9 Modag GmbH Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.10 Neuropore Therapies Inc Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.11 Prana Biotechnology Ltd Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
3.12 United Neuroscience Inc Multiple System Atrophy (Shy-Drager Syndrome) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 1 Drug Details
4.2 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 1 Drug Overview
4.3 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 2 Drug Details
5.2 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 2 Drug Overview
5.3 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 3 Drug Details
6.2 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 3 Drug Overview
6.3 Multiple System Atrophy (Shy-Drager Syndrome)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Multiple System Atrophy (Shy-Drager Syndrome)- Pre-clinical Phase Drug Details
7.2 Multiple System Atrophy (Shy-Drager Syndrome)- Pre-clinical Phase Drug Overview
7.3 Multiple System Atrophy (Shy-Drager Syndrome)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
